Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Capital Expenditures of $2.5 million for Q1 2026, down 51.44% year-over-year from $5.1 million in Q1 2025, and down 77.18% quarter-over-quarter from $10.8 million in Q4 2025.
Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Capital Expenditures for 10 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 51.44% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $6.9 million (up 67.23% YoY), while the FY2025 annual figure was $9.5 million, up 697.15% from the prior year.
- Capital Expenditures fell to $2.5 million in Q1 2026 per DNLI's latest filing, from $10.8 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $12.9 million in Q4 2023 and bottomed at -$10.7 million in Q3 2025.
- Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of $2.5 million in 2026.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 3225.0% — and 2025, when it jumped 77092.86%.
- Denali Therapeutics' Capital Expenditures stood at -$284000.0 in 2022, then surged by 4655.99% to $12.9 million in 2023, then sank by 99.89% to $14000.0 in 2024, then surged by 77092.86% to $10.8 million in 2025, then tumbled by 77.18% to $2.5 million in 2026.
- Business Quant data shows DNLI's Capital Expenditures at $2.5 million in Q1 2026, $10.8 million in Q4 2025, and -$10.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 805,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 805,000.00 |
| Jun 30, 2026 | 805,000.00 |
| Mar 31, 2026 | 2.47 Mn |
| Mar 31, 2026 | 2.47 Mn |
| Dec 31, 2025 | 10.81 Mn |
| Dec 31, 2025 | 10.81 Mn |
| Sep 30, 2025 | -10.66 Mn |
| Sep 30, 2025 | -10.66 Mn |
| Jun 30, 2025 | 4.28 Mn |
| Jun 30, 2025 | 4.28 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | -5.76 Mn |
| Sep 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | 4.79 Mn |
| Jun 30, 2024 | 4.79 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |